- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04937907
Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS) (CHXLAS)
Efficacy and Safety of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS)
Study Overview
Status
Conditions
Detailed Description
This Phase 2 randomized controlled trial will study the safety, tolerability, and efficacy of Hydroxychloroquine in qualified patients with Alport syndrome. The trial will be open-label, randomized, controlled and will enroll up to 50 patients.
Patients in the Phase 2 cohort will be randomized 1:1 to either Hydroxychloroquine Cohort or Comparator Cohort.
All patients in the study will follow the same visit and assessment schedule. Following randomization on Day 1, patients will be scheduled to be assessed during treatment at Weeks 4, 12, and 24. Patients will not receive study drug during a 24-week withdrawal period between Weeks 25 and 48. Patients will also be scheduled to be assessed at an in person follow up visit at Week 36, and 48.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Wen-yan Huang, PHD
- Phone Number: +8618964025491
- Email: huangwenyan@sjtu.edu.cn
Study Contact Backup
- Name: Lei Sun, MD
- Phone Number: +8618817821787
- Email: sunlei@shchildren.com.cn
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200062
- Recruiting
- Shanghai Children's Hospital
-
Contact:
- Wen-yan Huang, PHD
- Phone Number: +8618964025491
- Email: huangwenyan@sjtu.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female;
- Age 3-18 years old;
- Diagnosis of Alport syndrome by genetic testing (documented mutation in a gene associated with Alport syndrome, including COL4A3, COL4A4, or COL4A5) or histologic assessment using electron microscopy;
- Screening eGFR ≥ 90 mL/min/1.73 m2;
- ACE inhibitor and/or ARB, the dosing regimen should be stable for at least 4 weeks prior to screening;
- No antirheumatic drugs such as hydroxychloroquine have been used;
- Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures;
Exclusion Criteria:
- Causes of chronic kidney disease aside from Alport syndrome (including but not limited to other heritable disorders leading to chronic kidney disease, diabetic nephropathy, hypertensive nephropathy, lupus nephritis, IgA nephropathy);
- Prior exposure to hydroxychloroquine;
- Ongoing chronic hemodialysis or peritoneal dialysis therapy;
- Renal transplant recipient;
- Any clinically significant illness within 4 weeks before screening or surgical or medical condition (other than Alport syndrome) that could interfere with the subject's study compliance; confound the study results; impact subject safety; or significantly alter the absorption, distribution, metabolism, or excretion of drugs;
- Participation in other interventional clinical studies;
- Known hypersensitivity to any component of the study drug.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Hydroxychloroquine Cohort
Patients in the cohort will receive Hydroxychloroquine(HCQ) throughout the study.Patients administered HCQ by oral at a dose of 6.5mg per kilogram twice a day for 6 months.
During treatment with HCQ, patients also received enalapril(5-10mg qd).
|
Patients administered HCQ by oral at a dose of 6.5mg per kilogram twice a day at least 6 months.
Other Names:
Patients administered Benazepril by oral at a dose of 5mg or 10mg once a day at least 6 months.
Other Names:
|
Sham Comparator: Comparator Cohort
During treatment with HCQ, Patients randomized to Comparator Cohort only received enalapril(5-10mg qd).
|
Patients administered Benazepril by oral at a dose of 5mg or 10mg once a day at least 6 months.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in urinary erythrocyte count(/HP)
Time Frame: Baseline to maximum 48 weeks
|
To assess the change in urinary erythrocyte count(/HP) from baseline to week 48 for patients receiving active drug, compared to patients in Comparator Cohort.
|
Baseline to maximum 48 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in 24-hour urinary protein quantity
Time Frame: Baseline to maximum 48 weeks
|
To assess the change in 24-hour urinary protein quantity from baseline to week 48 for patients receiving active drug, compared to patients in Comparator Cohort.
|
Baseline to maximum 48 weeks
|
Change in urinary albumin characterization
Time Frame: Baseline to maximum 48 weeks
|
To assess the change in urinary albumin characterization from baseline to week 48 for patients receiving active drug, compared to patients in Comparator Cohort.
|
Baseline to maximum 48 weeks
|
Change in urinary albumin to creatinine ratio
Time Frame: Baseline to maximum 48 weeks
|
To assess the change in urinary albumin to creatinine ratio from baseline to week 48 for patients receiving active drug, compared to patients in Comparator Cohort.
|
Baseline to maximum 48 weeks
|
Change in urinary erythrocyte count(urinary sediment analyzer)
Time Frame: Baseline to maximum 48 weeks
|
To assess the change in urinary erythrocyte count(urinary sediment analyzer) from baseline to week 48 for patients receiving active drug, compared to patients in Comparator Cohort.
|
Baseline to maximum 48 weeks
|
Change in eGFR from baseline
Time Frame: Baseline to maximum 48 weeks
|
To assess the increase in eGFR from baseline to week 48 for patients receiving active drug, compared to patients in Comparator Cohort.
|
Baseline to maximum 48 weeks
|
Number of participants with treatment-related adverse events
Time Frame: Baseline to maximum 48 weeks
|
Safety will be assessed by monitoring adverse events, physical examinations and clinical laboratory test through 48 weeks.
|
Baseline to maximum 48 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Wen-yan Huang, PhD, Shanghai Children's Hospital
Publications and helpful links
General Publications
- Schrezenmeier E, Dorner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020 Mar;16(3):155-166. doi: 10.1038/s41584-020-0372-x. Epub 2020 Feb 7.
- Hertz JM, Thomassen M, Storey H, Flinter F. Clinical utility gene card for: Alport syndrome - update 2014. Eur J Hum Genet. 2015 Sep;23(9). doi: 10.1038/ejhg.2014.254. Epub 2014 Nov 12. No abstract available.
- Daga S, Donati F, Capitani K, Croci S, Tita R, Giliberti A, Valentino F, Benetti E, Fallerini C, Niccheri F, Baldassarri M, Mencarelli MA, Frullanti E, Furini S, Conticello SG, Renieri A, Pinto AM. New frontiers to cure Alport syndrome: COL4A3 and COL4A5 gene editing in podocyte-lineage cells. Eur J Hum Genet. 2020 Apr;28(4):480-490. doi: 10.1038/s41431-019-0537-8. Epub 2019 Nov 21. Erratum In: Eur J Hum Genet. 2023 Jan 18;:
- Yang YZ, Chen P, Liu LJ, Cai QQ, Shi SF, Chen YQ, Lv JC, Zhang H. Comparison of the effects of hydroxychloroquine and corticosteroid treatment on proteinuria in IgA nephropathy: a case-control study. BMC Nephrol. 2019 Aug 5;20(1):297. doi: 10.1186/s12882-019-1488-6.
- Liu LJ, Yang YZ, Shi SF, Bao YF, Yang C, Zhu SN, Sui GL, Chen YQ, Lv JC, Zhang H. Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial. Am J Kidney Dis. 2019 Jul;74(1):15-22. doi: 10.1053/j.ajkd.2019.01.026. Epub 2019 Mar 25.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Kidney Diseases
- Urologic Diseases
- Disease
- Urogenital Abnormalities
- Congenital Abnormalities
- Connective Tissue Diseases
- Nephritis
- Collagen Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Syndrome
- Nephritis, Hereditary
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Anti-Infective Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Protease Inhibitors
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Angiotensin-Converting Enzyme Inhibitors
- Benazepril
- Hydroxychloroquine
Other Study ID Numbers
- 2021SPNR001
- 2019YLYM06 (Other Grant/Funding Number: Shanghai Children's Hospital)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alport Syndrome, X-Linked
-
University of California, DavisUniversity of Alberta; St. Justine's HospitalRecruitingNeurobehavioral Manifestations | Genetic Diseases, X-Linked | Intellectual Disability | Fragile X Syndrome | Sex Chromosome Disorders | Fragile X Mental Retardation Syndrome | Trinucleotide Repeat Expansion | Fra(X) Syndrome | FXS | Mental Retardation, X LinkedUnited States, Canada
-
The Hospital for Sick ChildrenCompletedX-linked Lymphoproliferative Syndrome Type 2 (XLP-2)Canada
-
National Eye Institute (NEI)Active, not recruiting
-
Ovid Therapeutics Inc.CompletedFragile X Syndrome (FXS)United States
-
Guido A. Davidzon, MD, SMWithdrawn
-
Tetra Discovery PartnersCompletedFragile X Syndrome | Fra(X) Syndrome | FXSUnited States
-
Eunice Kennedy Shriver National Institute of Child...University of WashingtonUnknownWiskott-Aldrich Syndrome | Leukocyte Adhesion Deficiency Syndrome | X-Linked Agammaglobulinemia | X-Linked Hyper IgM SyndromeUnited States
-
Marinus PharmaceuticalsUniversity of California, Davis; U.S. Army Medical Research and Development...Completed
-
RTI InternationalEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedFragile X Syndrome (FXS)United States
-
National Eye Institute (NEI)CompletedRetinoschisis | X-LinkedUnited States
Clinical Trials on Hydroxychloroquine Sulfate 100 milligram (mg) Tab
-
Tan Tock Seng HospitalNetherlands: Ministry of Health, Welfare and Sports; Duke-NUS Graduate Medical... and other collaboratorsWithdrawnCoronavirus Infection | Hydroxychloroquine Adverse Reaction
-
Shaheed Zulfiqar Ali Bhutto Medical UniversityUnknown
-
Ravi Amaravadi, MDTerminatedCOVID-19United States
-
Genuine Research Center, EgyptBio Med for Pharmaceuticals Industries (BIOMED), EgyptCompleted
-
Patrick HensleyActive, not recruitingProstate Cancer RecurrentUnited States
-
SandozCompletedImmunosuppression | Rheumatism
-
Cambridge University Hospitals NHS Foundation TrustUniversity of CambridgeWithdrawn
-
Eisai Inc.Active, not recruitingBreast Neoplasms | Receptors, Estrogen | Genes, Erbb-2United States, United Kingdom
-
First Affiliated Hospital of Harbin Medical UniversityUnknown
-
Taoyuan General HospitalNational Health Research Institutes, Taiwan; Centers for Disease Control, Taiwan and other collaboratorsCompletedCoronavirus InfectionTaiwan